MULTIPLE SCLEROSIS · White paper
Multiple Sclerosis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About multiple sclerosis — and why its trials are hard
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system in which autoimmune attack on myelin causes inflammation, demyelination, and progressive neurodegeneration. It is usually diagnosed between ages 20-50, is two-to-three times more common in women, and shows higher prevalence farther from the equator. Diagnosis follows the McDonald criteria (2017 revision) integrating clinical and MRI evidence of dissemination in space and time. Disease-modifying therapy has evolved from interferon betas and glatiramer acetate to oral agents (dimethyl fumarate, S1P modulators such as fingolimod, cladribine) and high-efficacy monoclonal antibodies (natalizumab, ocrelizumab, ofatumumab). Ocrelizumab is notable as the first therapy approved for primary progressive MS. Pivotal endpoints include annualized relapse rate, confirmed disability progression on the EDSS, MRI lesion activity, brain volume loss, and the composite NEDA. Progressive MS remains a graveyard for trials: opicinumab, rituximab in PPMS, and the MS-SMART agents failed to slow progression, reflecting disease heterogeneity and the limits of relapse-based endpoints.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Glatiramer acetate (Copaxone) | 1996 | Relapsing-remitting MS (immunomodulator) | Pivotal RRMS trial (Johnson et al.) | Relapse rate | ~29% reduction in relapse rate vs placebo |
| Natalizumab (Tysabri) | 2004 | Relapsing MS (anti-VLA-4 alpha-4 integrin antibody; 2004 approval, reintroduced 2006 with REMS) | AFFIRM | Annualized relapse rate and disability progression | ~68% relative reduction in annualized relapse rate vs placebo at 1 year |
| Fingolimod (Gilenya) | 2010 | Relapsing MS (first oral therapy; sphingosine-1-phosphate receptor modulator) | FREEDOMS | Annualized relapse rate | ~54% reduction in annualized relapse rate vs placebo (0.5 mg) |
| Ocrelizumab (Ocrevus) | 2017 | Relapsing MS and primary progressive MS (anti-CD20 B-cell monoclonal antibody; first PPMS therapy) | OPERA I/II (RMS); ORATORIO (PPMS) | Annualized relapse rate (OPERA); confirmed disability progression (ORATORIO) | ~46-47% lower ARR vs interferon beta-1a; ORATORIO reduced 12-week confirmed disability progression (~24% relative) |
| Ofatumumab (Kesimpta) | 2020 | Relapsing MS (subcutaneous anti-CD20 monoclonal antibody) | ASCLEPIOS I and II | Annualized relapse rate vs teriflunomide | ARR ~0.11 vs ~0.22 (roughly 50-59% relative reduction vs teriflunomide) |
| Cladribine (Mavenclad) | 2019 | Relapsing forms of MS including active secondary progressive (oral selective immune reconstitution) | CLARITY | Annualized relapse rate | ~58% reduction in annualized relapse rate vs placebo (3.5 mg/kg) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in multiple sclerosis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Opicinumab (anti-LINGO-1) — SYNERGY (NCT01864148) / RENEW (optic neuritis, NCT01721161) | Failed to meet primary endpoint | No significant remyelination/disability benefit; complex non-linear dose response, heterogeneous repair biology |
| Rituximab — OLYMPUS (NCT00087529, PPMS) | Missed primary endpoint of slowing disability progression in PPMS | Different pathology in progressive vs relapsing MS; benefit limited to younger patients with inflammatory lesions |
| Amiloride, fluoxetine, riluzole — MS-SMART (NCT01910259, SPMS) | None of the three repurposed neuroprotectants slowed brain atrophy or disability | Incomplete understanding of progressive MS pathology; endpoints insensitive to neurodegeneration |
Choosing the right endpoint
Primary endpoints that matter in multiple sclerosis trials
- Annualized relapse rate (ARR) — Common primary endpoint reflecting acute CNS inflammation in relapsing MS
- Confirmed disability progression (EDSS) — Expanded Disability Status Scale change sustained at 12 or 24 weeks; key for progressive MS
- MRI lesion activity — New/enlarging T2 and gadolinium-enhancing lesions as surrogate inflammation markers
- Brain volume loss (atrophy) — Marker of neurodegeneration and long-term progression
- No Evidence of Disease Activity (NEDA) — Composite of no relapses, no MRI activity, and no EDSS progression
How iNGENū runs multiple sclerosis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Multiple Sclerosis clinical trials — FAQs
Why is progressive MS so hard to treat in trials?
What made ocrelizumab a milestone therapy?
What is NEDA and why does it matter?
Ready to discuss your multiple sclerosis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal